VLP Therapeutics (VLPT) develops cancer treatment vaccines and prophylactic vaccines against infectious diseases such as malaria and dengue using its proprietary VLP platform. The company is advancing multiple R&D programs with the stated goal of moving into clinical trials as soon as possible. VLPT was co-founded in 2013 by Wataru Akahata, Ryuji Ueno, and Sachiko Kuno and is led by CEO Wataru Akahata. The additional capital is intended to accelerate both cancer and infectious‑disease vaccine programs and broaden R&D efforts. Financially, the company recently secured a $21M Series A-1 and previously raised $16M in a Series A in March 2021. VLP Therapeutics is a Gaithersburg, Md.–based biotech company developing a cancer treatment vaccine and prophylactic vaccines against malaria, dengue and COVID-19 using proprietary platform technologies. The company was co‑founded in 2013 by Drs. Wataru Akahata, Ryuji Ueno and Sachiko Kuno. It focuses on research and development of vaccine candidates built on virus‑like particle (VLP) technologies. In March 2021 VLP Therapeutics completed a Series A financing totaling $16m. The company intends to use the funds to advance R&D and move its cancer treatment vaccine into clinical trials at the earliest date possible. No operating metrics were disclosed in the article.

Total raised

$37M

Funding rounds

2

Latest round

Series A

Latest activity

Dec 2021